Fiche publication
Date publication
octobre 2025
Journal
Liver international : official journal of the International Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
,
Pr MANFREDI Sylvain
Tous les auteurs :
Allaire M, Thiam EM, Amaddeo G, Bouattour M, Edeline J, Brusset B, Ziol M, Merle P, Blanc JF, Uguen T, Ganne N, Cattan S, Riachi G, Loustaud-Ratti V, Decaens T, Silvain C, Peron JM, Baron A, Pageaux GP, Oberti F, Anty R, Pascale A, Manfredi S, Bourliere M, Nousbaum JB, Heurgue A, Ollivier-Hourmand I, Lequoy M, Bronowicki JP, Villing AL, Ducournau G, Ganry O, Costentin C, Nguyen-Khac E
Lien Pubmed
Résumé
Atezolizumab-Bevacizumab (AtezoBev) was the first immunotherapy approved for hepatocellular carcinoma (HCC) in France, with initial trials primarily involving patients with viral-related liver disease. This prospective study aimed to evaluate the efficacy of AtezoBev in a French HCC population predominantly affected by non-viral liver disease.
Mots clés
atezolizumab‐bevacizumab, hepatocellular carcinoma, overall survival, prognostic factors, real life study, response
Référence
Liver Int. 2025 10;45(10):e70337
